Chen, Hongrui
Sun, Bin
Chang, Shih-Jen
Yu, Zhang
Qiu, Yajing
Hua, Chen
Lin, Xiaoxi
Funding for this research was provided by:
Major and Key Cultivation Projects of Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine (JYZP005)
Treatment and mechanism of PI3K/mTOR dual-target inhibitor (WX390) on PIK3CA-related overgrowth spectrum (JYWO22075)
Fundamental Research Funds for the Central Universities (YG2023ZD13)
Shanghai Key Research Center - Shanghai Research Center for Plastic Surgery (2023ZZ02023)
Article History
Received: 9 May 2024
Accepted: 5 July 2024
First Online: 18 July 2024
Declarations
:
: The study was approved by the Ethics Board of Shanghai Ninth Hospital, Shanghai Jiaotong University of Medicine (SH9H-2022-T215-1). Written informed consent forms were signed by patients’ parents whose photographs were presented in this study. Title of the approved project: Treatment and mechanism of Pl3K/mTOR dual-target inhibitor (WX390) on PlK3CA-related overgrowth spectrum (PROS). Date of approval: 06, October, 2022.
: The consent for publication was acquired from patients’ parents. All authors confirm their consent for publication.
: The authors declare that they have no competing interests.